Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 16/20 | 0.83 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.83 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.83 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655828 | 1.00 | PIK3CG (0.83) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL8616 | 0.97 | PIK3CD (0.89) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655785 | 0.97 | PIK3CD (0.89) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11538 | 0.96 | PIK3CD (0.86) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655804 | 0.96 | PIK3CD (0.86) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655795 | 0.92 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11525 | 0.92 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11669 | 0.92 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31655817 | 0.92 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL9623 | 0.91 | PIK3CD (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | claimed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | claimed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | claimed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | claimed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | claimed |
| US-20220054563-A1 | DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | AKAMIS BIO, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11173186-B2 | Dosing regime and formulations for type B adenovirus | PSIOXUS THERAPEUTICS LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| EP-3777870-A1 | A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | Psioxus Therapeutics Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3007711-B1 | A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | PSIOXUS THERAPEUTICS LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3R1 4842/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3R1 4842/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3R1 4842/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CG 3708/4885PIK3CD 4224/4885PIK3R1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.